help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arvat, E.
Right arrow Articles by Ghigo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arvat, E.
Right arrow Articles by Ghigo, E.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 7 3176-3181
Copyright © 2001 by The Endocrine Society


Original Articles

Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans1

Emanuela Arvat, Barbara Maccagno, Roberta Giordano, Micaela Pellegrino, Fabio Broglio, Laura Gianotti, Mauro Maccario, Franco Camanni and Ezio Ghigo

Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, 10126 Turin, Italy

Address all correspondence and requests for reprints to: Ezio Ghigo, M.D., Divisione di Endocrinologia, Ospedale Molinette, C.so Dogliotti 14, 10126 Torino, Italy. E-mail: ezio.ghigo{at}unito.it

Abstract

Animal studies indicate that mineralocorticoid receptors (MR) in the hippocampus play a major role in the glucocorticoid feedback control of the hypothalamo-pituitary-adrenal (HPA) axis. Specifically, MR mediate the proactive feedback of glucocorticoids in the maintenance of basal HPA activity. The stimulatory effect of intracerebroventricular and intrahippocampal MR blockade on the HPA axis in animals has been clearly shown, whereas the effect of systemic administration of mineralocorticoid antagonists in humans is still contradictory. To clarify this point, in seven normal young women (aged 25–32 yr; body mass index, 19.0–23.0 kg/m2) we studied the effects of canrenoate (CAN; 200 mg as iv bolus at 2000 h, followed by 200 mg infused in 500 mL saline over 4 h up to 2400 h) or placebo (saline, 1.0 mL as iv bolus at 2000 h, followed by 500 mL over 4 h up to 2400 h) on the spontaneous ACTH, cortisol, dehydroepiandrosterone (DHEA) and aldosterone secretion as well as on the ACTH, cortisol, and DHEA responses to human CRH (2.0 µg/kg as iv bolus at 2200 h) or arginine vasopressin (AVP; 0.17 U/kg as im bolus at 2200 h). Blood samples were taken every 15 min from 2000–2400 h. During placebo, spontaneous ACTH and cortisol levels showed progressive decreases (P < 0.05) from 2000–2400 h (baseline vs. nadir, mean ± SEM, 2.0 ± 0.3 vs. 1.4 ± 0.2 pmol/L and 115.1 ± 23.7 vs. 63.5 ± 24.3 nmol/L), whereas DHEA and aldosterone levels did not change. CRH induced clear increases in ACTH, cortisol, and DHEA levels (peaks, mean ± SEM, 7.1 ± 1.1 vs. 1.6 ± 0.2 pmol/L, 322.9 ± 19.5 vs. 92.8 ± 24.5 nmol/L, and 44.2 ± 2.7 vs. 20.0 ± 3.0 nmol/L; P < 0.05). Similarly, AVP elicited significant increases in ACTH, cortisol, and DHEA levels (3.8 ± 0.3 vs. 1.5 ± 0.1 pmol/L, 211.9 ± 27.2 vs. 67.7 ± 9.7 nmol/L, and 51.6 ± 4.0 vs. 16.3 ± 2.0 nmol/L; P < 0.05). During CAN treatment, ACTH, cortisol, and DHEA levels showed progressive rises, which begun at approximately 60 min and peaked between 2300 and 2400 h (ACTH, 3.4 ± 0.4 vs. 1.1 ± 0.3 pmol/L; cortisol, 314.5 ± 49.6 vs. 123.3 ± 13.2 nmol/L; DHEA, 52.0 ± 8.8 vs. 21.0 ± 2.3 nmol/L; P < 0.05 vs. baseline as well as vs. the same time points during placebo). Aldosterone secretion was not modified by CAN. The ACTH, cortisol, and DHEA responses to human CRH were enhanced by CAN (10.0 ± 1.7 pmol/L, 462.2 ± 36.9 nmol/L, and 66.3 ± 8.8 nmol/L), although statistical significance (P < 0.05) was obtained for cortisol and DHEA only. Also the ACTH, cortisol and DHEA responses to AVP were amplified by CAN (8.0 ± 2.6 pmol/L, 324.0 ± 34.8 nmol/L, and 77.8 ± 4.0 nmol/L); again, statistical significance (P < 0.05) was obtained for cortisol and DHEA only. In conclusion, our study shows that the blockade of MR by CAN significantly enhances the activity of the HPA axis in humans, indicating a physiological role for MR in its control. These results also suggest that the stimulatory effect of CAN on HPA axis is mediated by concomitant modulation of CRH and AVP release.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
C. Mattsson, R. M. Reynolds, K. Simonyte, T. Olsson, and B. R. Walker
Combined Receptor Antagonist Stimulation of the Hypothalamic-Pituitary-Adrenal Axis Test Identifies Impaired Negative Feedback Sensitivity to Cortisol in Obese Men
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1347 - 1352.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
H. C. Atkinson, S. A. Wood, E. S. Castrique, Y. M. Kershaw, C. C. R. Wiles, and S. L. Lightman
Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor
Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1011 - E1022.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Peters, M. Conrad, C. Hubold, U. Schweiger, B. Fischer, and H. L. Fehm
The principle of homeostasis in the hypothalamus-pituitary-adrenal system: new insight from positive feedback
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R83 - R98.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. M. Rozeboom, H. Akil, and A. F. Seasholtz
Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice
PNAS, March 13, 2007; 104(11): 4688 - 4693.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. H. DeRijk, S. Wust, O. C. Meijer, M.-C. Zennaro, I. S. Federenko, D. H. Hellhammer, G. Giacchetti, E. Vreugdenhil, F. G. Zitman, and E. R. de Kloet
A Common Polymorphism in the Mineralocorticoid Receptor Modulates Stress Responsiveness
J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5083 - 5089.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Giordano, M. Bo, M. Pellegrino, M. Vezzari, M. Baldi, A. Picu, M. Balbo, L. Bonelli, G. Migliaretti, E. Ghigo, et al.
Hypothalamus-Pituitary-Adrenal Hyperactivity in Human Aging Is Partially Refractory to Stimulation by Mineralocorticoid Receptor Blockade
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5656 - 5662.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. W. W. Pace and R. L. Spencer
Disruption of mineralocorticoid receptor function increases corticosterone responding to a mild, but not moderate, psychological stressor
Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1082 - E1088.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Wellhoener, J. Born, H. L. Fehm, and C. Dodt
Elevated Resting and Exercise-Induced Cortisol Levels after Mineralocorticoid Receptor Blockade with Canrenoate in Healthy Humans
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5048 - 5052.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. R. Plovsing, C. Wamberg, N. C. F. Sandgaard, J. A. Simonsen, N.-H. Holstein-Rathlou, P. F. Hoilund-Carlsen, and P. Bie
Effects of truncated angiotensins in humans after double blockade of the renin system
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R981 - R991.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
C. Otte, A. Yassouridis, H. Jahn, P. Maass, N. Stober, K. Wiedemann, and M. Kellner
Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans
J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2003; 58(10): B900 - 905.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Mattsson, M. Lai, J. Noble, E. McKinney, J. L. Yau, J. R. Seckl, and B. R. Walker
Obese Zucker Rats Have Reduced Mineralocorticoid Receptor and 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression in Hippocampus--Implications for Dysregulation of the Hypothalamic-Pituitary-Adrenal Axis in Obesity
Endocrinology, July 1, 2003; 144(7): 2997 - 3003.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. Kellner, D. G. Baker, A. Yassouridis, S. Bettinger, C. Otte, D. Naber, and K. Wiedemann
Mineralocorticoid Receptor Function in Patients With Posttraumatic Stress Disorder
Am J Psychiatry, November 1, 2002; 159(11): 1938 - 1940.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Grottoli, R. Giordano, B. Maccagno, M. Pellegrino, E. Ghigo, and E. Arvat
The Stimulatory Effect of Canrenoate, a Mineralocorticoid Antagonist, on the Activity of the Hypothalamus-Pituitary-Adrenal Axis Is Abolished by Alprazolam, a Benzodiazepine, in Humans
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4616 - 4620.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society